Mr. Whelan clarified the investigation of bioelectronics, the incessant agony advertise, the broad item portfolio, and its honor winning "Best OTC Marketing Campaign on a Small Budget"
FREDERICK, MD- - (Marketwired - Oct 27, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the creator of cutting edge nonprescription dispensable $30.00 neuromodulation torment alleviation restorative gadgets, is satisfied to discharge a meeting with President, Andy Whelan. The meeting can be heard at http://westbrookradio.com/2016/10/26/andrew-whelan-president bioelectronics-corp-biel/
Mr. Whelan clarified the study of bioelectronics, the ceaseless agony advertise, the sweeping item portfolio, its honor winning "Best OTC Marketing Campaign on a Small Budget," and its appraisal of 12,000+ clients and the excellent item acknowledgment.
Perpetual Pain - 20% of grown-ups all around experiences incessant torment. This market is bigger than diabetes, coronary illness, and malignancy consolidated. ActiPatch is a nonprescription restorative gadget that addresses the neglected requirement for 1.5 billion perpetual torment sufferers worldwide that changes the way the focal sensory system works. The change brings about an expansion in torment recognition from less incitement. ActiPatch regulates the body's nerve movement to hose the agony recognition, in this manner alleviating the utilization of medications. Kenneth McLeod, Ph.D. Executive of Clinical Science and Engineering Research, New York State University Binghamton's short video clarifies how the innovation and ActiPatch function at http://actipatch.com/why-actipatch/.
Shown Marketability to Consumers - The Company's Try and Tell deals and promoting effort has won the current year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" grant. ActiPatch treatment is the main pain relieving in Walgreens/Boots in the UK.
Current unending torment treatments don't address the issue for endless torment alleviation and sufferers are incredulous. To defeat the doubt and quicken item acknowledgment, we advance a marked down 7-Day Trial gadget without an on/off switch. 65% of analyzers arrived at the midpoint of a 57% lessening in torment and said they "proposed" to or would "perhaps" buy. 80% purchased a normal of 1.75 gadgets inside 90-days. Following one year, the clients obtained a normal of 2.7 gadgets.
A main torment administration restorative diary Pain Management distributed a 5,000+ subject study: A UK registry investigation of the adequacy of another over-the-counter endless torment treatment, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35. The information shows a predictable clinically important impact in interminable musculoskeletal torment from an assortment of causes (osteoarthritis, rheumatoid joint pain, fibromyalgia, post-surgical, neuropathic) influencing distinctive districts of the body (back, hip, knee, wrist, elbow, and shoulder).
Also, our 6 month Observation Study illustrates:
Treatment sturdiness: Over 90% of the members reported proceeded with help averaging a 61% lessening in agony even following six months.
Diminished drug utilize: 86% reported an abatement in prescription utilize that kept on enhancing after some time. In particular, this lessening included remedy opiate based medications.
Enhanced personal satisfaction: 90% reported enhanced rest, 89% reported more prominent physical movement, and 71% reported their personal satisfaction was vastly improved to significantly better.
Social insurance reserve funds: 65% spent less on torment treatments and 65% reported less visits to the specialist and agony authority.
Diminished unfriendly occasions from drug utilize: 68% were encountering unfavorable symptoms, of these 71% reported a decrease in antagonistic reactions.
Reactions: None reported
US FDA OTC Market Clearance - The Company has presented a 510(k) pre showcase application to the FDA with three ActiPatch randomized clinical trials. Also, the clinical trials confirmation is being supplemented with a Registry of a 5,600 customer appraisal on back torment, a 6-Month Observational Study on item sturdiness, a Medication Use Reduction Study and a Sleep Improvement Study.
Mr. Whelan likewise clarified the innovation's critical open doors in menstrual agony, heel torment, headache migraines, diabetic neuropathy, postoperative surgery, constant injuries, bone development incitement, and different applications.
About BioElectronics Corporation
BioElectronics Corporation is the producer of a main group of reasonable, dispensable, sedate free, restorative gadgets. ActiPatch® Therapy, over-the-counter treatment for back agony and other musculoskeletal dissensions; RecoveryRx® Devices for interminable and post-agent wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. If you don't mind visit www.bielcorp.com for clinical proof and a video on how it functions.
FREDERICK, MD- - (Marketwired - Oct 27, 2016) - BioElectronics Corporation (OTC PINK: BIEL), the creator of cutting edge nonprescription dispensable $30.00 neuromodulation torment alleviation restorative gadgets, is satisfied to discharge a meeting with President, Andy Whelan. The meeting can be heard at http://westbrookradio.com/2016/10/26/andrew-whelan-president bioelectronics-corp-biel/
Mr. Whelan clarified the study of bioelectronics, the ceaseless agony advertise, the sweeping item portfolio, its honor winning "Best OTC Marketing Campaign on a Small Budget," and its appraisal of 12,000+ clients and the excellent item acknowledgment.
Perpetual Pain - 20% of grown-ups all around experiences incessant torment. This market is bigger than diabetes, coronary illness, and malignancy consolidated. ActiPatch is a nonprescription restorative gadget that addresses the neglected requirement for 1.5 billion perpetual torment sufferers worldwide that changes the way the focal sensory system works. The change brings about an expansion in torment recognition from less incitement. ActiPatch regulates the body's nerve movement to hose the agony recognition, in this manner alleviating the utilization of medications. Kenneth McLeod, Ph.D. Executive of Clinical Science and Engineering Research, New York State University Binghamton's short video clarifies how the innovation and ActiPatch function at http://actipatch.com/why-actipatch/.
Shown Marketability to Consumers - The Company's Try and Tell deals and promoting effort has won the current year's OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" grant. ActiPatch treatment is the main pain relieving in Walgreens/Boots in the UK.
Current unending torment treatments don't address the issue for endless torment alleviation and sufferers are incredulous. To defeat the doubt and quicken item acknowledgment, we advance a marked down 7-Day Trial gadget without an on/off switch. 65% of analyzers arrived at the midpoint of a 57% lessening in torment and said they "proposed" to or would "perhaps" buy. 80% purchased a normal of 1.75 gadgets inside 90-days. Following one year, the clients obtained a normal of 2.7 gadgets.
A main torment administration restorative diary Pain Management distributed a 5,000+ subject study: A UK registry investigation of the adequacy of another over-the-counter endless torment treatment, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35. The information shows a predictable clinically important impact in interminable musculoskeletal torment from an assortment of causes (osteoarthritis, rheumatoid joint pain, fibromyalgia, post-surgical, neuropathic) influencing distinctive districts of the body (back, hip, knee, wrist, elbow, and shoulder).
Also, our 6 month Observation Study illustrates:
Treatment sturdiness: Over 90% of the members reported proceeded with help averaging a 61% lessening in agony even following six months.
Diminished drug utilize: 86% reported an abatement in prescription utilize that kept on enhancing after some time. In particular, this lessening included remedy opiate based medications.
Enhanced personal satisfaction: 90% reported enhanced rest, 89% reported more prominent physical movement, and 71% reported their personal satisfaction was vastly improved to significantly better.
Social insurance reserve funds: 65% spent less on torment treatments and 65% reported less visits to the specialist and agony authority.
Diminished unfriendly occasions from drug utilize: 68% were encountering unfavorable symptoms, of these 71% reported a decrease in antagonistic reactions.
Reactions: None reported
US FDA OTC Market Clearance - The Company has presented a 510(k) pre showcase application to the FDA with three ActiPatch randomized clinical trials. Also, the clinical trials confirmation is being supplemented with a Registry of a 5,600 customer appraisal on back torment, a 6-Month Observational Study on item sturdiness, a Medication Use Reduction Study and a Sleep Improvement Study.
Mr. Whelan likewise clarified the innovation's critical open doors in menstrual agony, heel torment, headache migraines, diabetic neuropathy, postoperative surgery, constant injuries, bone development incitement, and different applications.
About BioElectronics Corporation
BioElectronics Corporation is the producer of a main group of reasonable, dispensable, sedate free, restorative gadgets. ActiPatch® Therapy, over-the-counter treatment for back agony and other musculoskeletal dissensions; RecoveryRx® Devices for interminable and post-agent wound care; HealFast® Therapy and the Allay® Menstrual Pain Therapy. If you don't mind visit www.bielcorp.com for clinical proof and a video on how it functions.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.